Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
Public ClinicalTrials.gov record NCT01254773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
Study identification
- NCT ID
- NCT01254773
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 146 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2010 (Type not available)
- Primary completion
- Jan 2013 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- May 9, 2014
2010 – 2013
United States locations
- U.S. sites
- 28
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Janssen AI Investigational Site | Tucson | Arizona | 85724 | — |
| Janssen AI Investigational Site | Tucson | Arizona | 85741 | — |
| Janssen AI Investigational Site | La Habra | California | 90631 | — |
| Janssen AI Investigational Site | Lomita | California | 90277 | — |
| Janssen AI Investigational Site | Long Beach | California | 90806 | — |
| Janssen AI Investigational Site | Oceanside | California | 92056 | — |
| Janssen AI Investigational Site | Pasadena | California | 91105 | — |
| Janssen AI Investigational Site | Santa Monica | California | 90404 | — |
| Janssen AI Investigational Site | Sherman Oaks | California | 91403 | — |
| Janssen AI Investigational Site | Deerfield Beach | Florida | 33064 | — |
| Janssen AI Investigational Site | Delray Beach | Florida | 33445 | — |
| Janssen AI Investigational Site | Fort Meyers | Florida | 33919 | — |
| Janssen AI Investigational Site | Miami Springs | Florida | 33166 | — |
| Janssen AI Investigational Site | South Miami | Florida | 33143 | — |
| Janssen AI Investigational Site | Atlanta | Georgia | 30322 | — |
| Janssen AI Investigational Site | Indianapolis | Indiana | 46202 | — |
| Janssen AI Investigational Site | Kansas City | Kansas | 66160 | — |
| Janssen AI Investigational Site | Lexington | Kentucky | 40536 | — |
| Janssen AI Investigational Site | Plymouth | Massachusetts | 02360 | — |
| Janssen AI Investigational Site | Farmington Hills | Michigan | 48334 | — |
| Janssen AI Investigational Site | Creve Coeur | Missouri | 63141 | — |
| Janssen AI Investigational Site | St Louis | Missouri | 63104 | — |
| Janssen AI Investigational Site | Latham | New York | 12210 | — |
| Janssen AI Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Janssen AI Investigational Site | Dayton | Ohio | 45417 | — |
| Janssen AI Investigational Site | Portland | Oregon | 97239 | — |
| Janssen AI Investigational Site | Philadelphia | Pennsylvania | 19102 | — |
| Janssen AI Investigational Site | Providence | Rhode Island | 02903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01254773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 9, 2014 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01254773 live on ClinicalTrials.gov.